The use of serotonin norepinephrine reuptake inhibitors (SNRIs), but not selective serotonin reuptake inhibitors, to treat acute-phase major depressive disorder in elderly patients is associated with a higher risk of adverse events, a recent meta-analysis has shown.
Dissatisfaction with body image is common among men receiving androgen deprivation therapy (ADT), a new study has shown. Exercise is seen as a means to counterbalance the side effect of treatment and improve mood.
Aripiprazole augmentation early in treatment is useful for inducing response in major depressive disorder, although caution should be exercised when increasing the dose to >6 mg/day, a study has shown.
Atrial fibrillation (AF) carries an excess risk of stroke recurrence independent of comorbidity with and heart failure (HF), while HF without AF also poses a significant risk of recurrence, a study has shown.
Men with metastatic hormone-sensitive prostate cancer (mHSPC) who receive testosterone suppression therapy may have a better survival outcome with the addition of enzalutamide over other non-steroidal anti-androgen (NSAA) therapies, according to the phase III ENZAMET* trial.